Elmind Capital LP Acquires New Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Elmind Capital LP bought a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 112,000 shares of the company's stock, valued at approximately $2,011,520. Amylyx Pharmaceuticals accounts for approximately 0.0% of Elmind Capital LP's portfolio, making the stock its 28th biggest holding. Elmind Capital LP owned approximately 0.10% of Amylyx Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. GSA Capital Partners LLP purchased a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth about $705,000. Dimensional Fund Advisors LP raised its holdings in shares of Amylyx Pharmaceuticals by 17.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company's stock valued at $12,544,000 after purchasing an additional 131,944 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Amylyx Pharmaceuticals by 15.5% in the 1st quarter. Bank of New York Mellon Corp now owns 251,104 shares of the company's stock worth $3,490,000 after purchasing an additional 33,757 shares during the last quarter. Vanguard Group Inc. raised its holdings in Amylyx Pharmaceuticals by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 5,804,912 shares of the company's stock worth $70,123,000 after purchasing an additional 531,162 shares during the period. Finally, Siren L.L.C. bought a new position in shares of Amylyx Pharmaceuticals in the first quarter valued at about $17,097,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX traded down $2.53 during trading hours on Friday, hitting $34.65. The stock had a trading volume of 1,091,088 shares, compared to its average volume of 1,680,063. Amylyx Pharmaceuticals, Inc. has a 12 month low of $9.15 and a 12 month high of $41.14. The stock has a fifty day moving average price of $22.15 and a 200 day moving average price of $17.37. The firm has a market capitalization of $3.86 billion, a PE ratio of -24.23 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). As a group, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares of the company's stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Robert W. Baird upped their price objective on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a report on Wednesday, August 19th. Mizuho boosted their target price on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a research note on Tuesday, August 18th. Citigroup increased their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Finally, Wall Street Zen cut Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $36.50.

About Amylyx Pharmaceuticals